08:58 AM EST, 01/26/2026 (MT Newswires) -- LB Pharmaceuticals ( LBRX ) said Monday that it has initiated a phase 2 trial evaluating the efficacy and safety of LB-102 to treat patients with bipolar depression.

The biopharmaceutical company said it expects the two-arm, six-week trial to enroll approximately 320 patients with bipolar 1 depression at approximately 30 sites in the US, with topline results expected in Q1 of 2028.

LB Pharmaceuticals ( LBRX ) said the trial will compare LB-102 with a placebo.